Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;7(10):e2438222.
doi: 10.1001/jamanetworkopen.2024.38222.

Feasibility and Performance of a Point-of-Care Hepatitis C RNA Assay in a Community Supervision Cohort

Leah Harvey  1   2 , Brendan Jacka  3 , Lauri Bazerman  2 , Aurielle Thomas  2 , Marc Moody  4 , Risha Irvin  5 , Curt G Beckwith  1   2
Affiliations

Feasibility and Performance of a Point-of-Care Hepatitis C RNA Assay in a Community Supervision Cohort

Leah Harvey et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cross-sectional study examines the feasibility and clinical performance of a fingerstick point-of-care hepatitis C virus (HCV) RNA assay in a community supervision (probation or parole) setting.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Irvin reported working part-time on federal detail at the National Institutes of Health on the national hepatitis C elimination plan. No other disclosures were reported.

References

    1. Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn. 2017;17(12):1109-1115. doi:10.1080/14737159.2017.1400385 - DOI - PubMed
    1. Trickey A, Fajardo E, Alemu D, Artenie AA, Easterbrook P. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(3):253-270. doi:10.1016/S2468-1253(22)00346-6 - DOI - PubMed
    1. Jacka BP, Bazerman LB, Dickerson C, et al. . Feasibility of hepatitis C virus testing and linkage in community supervision offices: great potential but persistent challenges. Int J Drug Policy. 2022;103:103668. doi:10.1016/j.drugpo.2022.103668 - DOI - PMC - PubMed
    1. Lafferty L, Cochrane A, Sheehan Y, Treloar C, Grebely J, Lloyd AR. “That was quick, simple, and easy”: patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. Int J Drug Policy. 2022;99:103456. doi:10.1016/j.drugpo.2021.103456 - DOI - PubMed
    1. Food and Drug Administration . FDA permits marketing of first point-of-care hepatitis C RNA test. June 27, 2024. Accessed July 30, 2024. https://www.fda.gov/news-events/press-announcements/fda-permits-marketin...

Publication types